Utah Medical Products, Inc. (NASDAQ: UTMD) Stock Competitors & Peer Comparison
See UTMD's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for UTMD and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| UTMD | $74.40 | +5.28% | 237.6M | 22.08 | $3.38 | +1.67% |
| ISRG | $385.13 | +1.90% | 133.2B | 39.21 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.13% |
| BDX | $184.20 | +0.71% | 51.2B | 14.30 | $13.00 | +2.13% |
| RMD | $227.67 | +2.10% | 33.3B | 21.32 | $10.77 | +1.06% |
| MDLN | $33.50 | +2.78% | 27.2B | 23.53 | $1.36 | N/A |
| WST | $361.98 | +1.91% | 25.7B | 42.93 | $8.50 | +0.24% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $90.53 | +0.79% | 15.6B | 12.69 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.13% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
UTMD vs ISRG Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, ISRG has a market cap of 133.2B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while ISRG trades at $385.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas ISRG's P/E ratio is 39.21. In terms of profitability, UTMD's ROE is +0.09%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, UTMD is less volatile compared to ISRG. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
UTMD vs BDXA Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas BDXA's P/E ratio is 45.70. In terms of profitability, UTMD's ROE is +0.09%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, UTMD is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
UTMD vs BDX Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, BDX has a market cap of 51.2B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while BDX trades at $184.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas BDX's P/E ratio is 14.30. In terms of profitability, UTMD's ROE is +0.09%, compared to BDX's ROE of +0.04%. Regarding short-term risk, UTMD is less volatile compared to BDX. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check BDX's competition here
ResMed Inc. (NYSE: RMD)
UTMD vs RMD Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, RMD has a market cap of 33.3B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while RMD trades at $227.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas RMD's P/E ratio is 21.32. In terms of profitability, UTMD's ROE is +0.09%, compared to RMD's ROE of +0.24%. Regarding short-term risk, UTMD is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check RMD's competition here
Medline Inc. (NASDAQ: MDLN)
UTMD vs MDLN Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, MDLN has a market cap of 27.2B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while MDLN trades at $33.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas MDLN's P/E ratio is 23.53. In terms of profitability, UTMD's ROE is +0.09%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, UTMD is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
UTMD vs WST Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, WST has a market cap of 25.7B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while WST trades at $361.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas WST's P/E ratio is 42.93. In terms of profitability, UTMD's ROE is +0.09%, compared to WST's ROE of +0.19%. Regarding short-term risk, UTMD is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
UTMD vs HOLX Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas HOLX's P/E ratio is 31.54. In terms of profitability, UTMD's ROE is +0.09%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, UTMD is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
UTMD vs SOLV Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, SOLV has a market cap of 15.6B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while SOLV trades at $90.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas SOLV's P/E ratio is 12.69. In terms of profitability, UTMD's ROE is +0.09%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, UTMD is less volatile compared to SOLV. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
UTMD vs BDXB Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas BDXB's P/E ratio is 7.60. In terms of profitability, UTMD's ROE is +0.09%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, UTMD is less volatile compared to BDXB. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
UTMD vs BAX Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, BAX has a market cap of 12.3B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while BAX trades at $23.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas BAX's P/E ratio is 11.39. In terms of profitability, UTMD's ROE is +0.09%, compared to BAX's ROE of -0.17%. Regarding short-term risk, UTMD is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check BAX's competition here
Avantor, Inc. (NYSE: AVTR)
UTMD vs AVTR Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, AVTR has a market cap of 10.4B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while AVTR trades at $15.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas AVTR's P/E ratio is 18.15. In terms of profitability, UTMD's ROE is +0.09%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, UTMD is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check AVTR's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
UTMD vs COO Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, COO has a market cap of 10.4B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while COO trades at $54.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas COO's P/E ratio is 11.68. In terms of profitability, UTMD's ROE is +0.09%, compared to COO's ROE of +0.07%. Regarding short-term risk, UTMD is less volatile compared to COO. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check COO's competition here
Repligen Corporation (NASDAQ: RGEN)
UTMD vs RGEN Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, RGEN has a market cap of 9.9B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while RGEN trades at $174.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas RGEN's P/E ratio is 97.07. In terms of profitability, UTMD's ROE is +0.09%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, UTMD is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check RGEN's competition here
AptarGroup, Inc. (NYSE: ATR)
UTMD vs ATR Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, ATR has a market cap of 8B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while ATR trades at $125.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas ATR's P/E ratio is 21.79. In terms of profitability, UTMD's ROE is +0.09%, compared to ATR's ROE of +0.14%. Regarding short-term risk, UTMD is less volatile compared to ATR. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
UTMD vs BLCO Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, BLCO has a market cap of 6.2B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while BLCO trades at $17.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas BLCO's P/E ratio is 26.52. In terms of profitability, UTMD's ROE is +0.09%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, UTMD is less volatile compared to BLCO. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
UTMD vs STVN Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, STVN has a market cap of 5.9B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while STVN trades at $21.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas STVN's P/E ratio is 32.57. In terms of profitability, UTMD's ROE is +0.09%, compared to STVN's ROE of +0.09%. Regarding short-term risk, UTMD is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check STVN's competition here
Teleflex Incorporated (NYSE: TFX)
UTMD vs TFX Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, TFX has a market cap of 5.7B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while TFX trades at $129.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas TFX's P/E ratio is 14.75. In terms of profitability, UTMD's ROE is +0.09%, compared to TFX's ROE of -0.32%. Regarding short-term risk, UTMD is less volatile compared to TFX. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
UTMD vs MMSI Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, MMSI has a market cap of 5.1B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while MMSI trades at $86.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas MMSI's P/E ratio is 22.04. In terms of profitability, UTMD's ROE is +0.09%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, UTMD is less volatile compared to MMSI. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check MMSI's competition here
Envista Holdings Corp (NYSE: NVST)
UTMD vs NVST Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, NVST has a market cap of 4B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while NVST trades at $25.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas NVST's P/E ratio is 16.85. In terms of profitability, UTMD's ROE is +0.09%, compared to NVST's ROE of +0.04%. Regarding short-term risk, UTMD is less volatile compared to NVST. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check NVST's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
UTMD vs ICUI Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while ICUI trades at $158.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas ICUI's P/E ratio is 19.46. In terms of profitability, UTMD's ROE is +0.09%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, UTMD is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check ICUI's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
UTMD vs PLSE Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, PLSE has a market cap of 3.8B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while PLSE trades at $49.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas PLSE's P/E ratio is -46.78. In terms of profitability, UTMD's ROE is +0.09%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, UTMD is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
UTMD vs ATRC Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, ATRC has a market cap of 2.9B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while ATRC trades at $56.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas ATRC's P/E ratio is 1745.96. In terms of profitability, UTMD's ROE is +0.09%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, UTMD is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check ATRC's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
UTMD vs XRAY Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, XRAY has a market cap of 2B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while XRAY trades at $10.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas XRAY's P/E ratio is 6.87. In terms of profitability, UTMD's ROE is +0.09%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, UTMD is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
UTMD vs LMAT Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while LMAT trades at $80.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas LMAT's P/E ratio is 29.69. In terms of profitability, UTMD's ROE is +0.09%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, UTMD is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check LMAT's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
UTMD vs BLFS Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, BLFS has a market cap of 1.8B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while BLFS trades at $36.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas BLFS's P/E ratio is -172.18. In terms of profitability, UTMD's ROE is +0.09%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, UTMD is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
UTMD vs AZTA Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, AZTA has a market cap of 1.5B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while AZTA trades at $33.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas AZTA's P/E ratio is 78.64. In terms of profitability, UTMD's ROE is +0.09%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, UTMD is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
UTMD vs KMTS Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, KMTS has a market cap of 1.5B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while KMTS trades at $24.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas KMTS's P/E ratio is -9.50. In terms of profitability, UTMD's ROE is +0.09%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, UTMD is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
UTMD vs STAA Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, STAA has a market cap of 1.1B. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while STAA trades at $22.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas STAA's P/E ratio is 39.38. In terms of profitability, UTMD's ROE is +0.09%, compared to STAA's ROE of +0.01%. Regarding short-term risk, UTMD is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
UTMD vs ATRI Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas ATRI's P/E ratio is 64.50. In terms of profitability, UTMD's ROE is +0.09%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, UTMD is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
UTMD vs ANGO Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, ANGO has a market cap of 648.1M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while ANGO trades at $15.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas ANGO's P/E ratio is -40.21. In terms of profitability, UTMD's ROE is +0.09%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, UTMD is less volatile compared to ANGO. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check ANGO's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
UTMD vs SMTI Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, SMTI has a market cap of 322.8M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while SMTI trades at $35.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas SMTI's P/E ratio is -585.17. In terms of profitability, UTMD's ROE is +0.09%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, UTMD is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check SMTI's competition here
Embecta Corp. (NASDAQ: EMBC)
UTMD vs EMBC Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, EMBC has a market cap of 302M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while EMBC trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas EMBC's P/E ratio is 1.96. In terms of profitability, UTMD's ROE is +0.09%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, UTMD is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check EMBC's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
UTMD vs NNNN Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, NNNN has a market cap of 241.8M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while NNNN trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas NNNN's P/E ratio is 79.62. In terms of profitability, UTMD's ROE is +0.09%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, UTMD is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
UTMD vs OSUR Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, OSUR has a market cap of 238.2M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while OSUR trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas OSUR's P/E ratio is -5.01. In terms of profitability, UTMD's ROE is +0.09%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, UTMD is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check OSUR's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
UTMD vs PDEX Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, PDEX has a market cap of 213.6M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while PDEX trades at $72.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas PDEX's P/E ratio is 16.20. In terms of profitability, UTMD's ROE is +0.09%, compared to PDEX's ROE of +0.31%. Regarding short-term risk, UTMD is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
UTMD vs KRMD Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, KRMD has a market cap of 145.1M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while KRMD trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas KRMD's P/E ratio is -79.00. In terms of profitability, UTMD's ROE is +0.09%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, UTMD is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
UTMD vs STXS Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, STXS has a market cap of 129.3M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while STXS trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas STXS's P/E ratio is -7.76. In terms of profitability, UTMD's ROE is +0.09%, compared to STXS's ROE of -1.33%. Regarding short-term risk, UTMD is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check STXS's competition here
Daxor Corporation (NASDAQ: DXR)
UTMD vs DXR Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, DXR has a market cap of 68M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while DXR trades at $11.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas DXR's P/E ratio is 9.47. In terms of profitability, UTMD's ROE is +0.09%, compared to DXR's ROE of +0.13%. Regarding short-term risk, UTMD is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check DXR's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
UTMD vs AKYA Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas AKYA's P/E ratio is -1.34. In terms of profitability, UTMD's ROE is +0.09%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, UTMD is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
UTMD vs STSS Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas STSS's P/E ratio is -0.02. In terms of profitability, UTMD's ROE is +0.09%, compared to STSS's ROE of -1.54%. Regarding short-term risk, UTMD is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
UTMD vs OMIC Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas OMIC's P/E ratio is -0.58. In terms of profitability, UTMD's ROE is +0.09%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, UTMD is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
UTMD vs IGAP Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas IGAP's P/E ratio is -10.52. In terms of profitability, UTMD's ROE is +0.09%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, UTMD is less volatile compared to IGAP. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
UTMD vs NEPH Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, NEPH has a market cap of 46.6M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while NEPH trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas NEPH's P/E ratio is 71.50. In terms of profitability, UTMD's ROE is +0.09%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, UTMD is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check NEPH's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
UTMD vs POCI Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, POCI has a market cap of 46.1M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while POCI trades at $4.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas POCI's P/E ratio is -6.68. In terms of profitability, UTMD's ROE is +0.09%, compared to POCI's ROE of -0.37%. Regarding short-term risk, UTMD is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check POCI's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
UTMD vs HBIO Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, HBIO has a market cap of 36M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while HBIO trades at $8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas HBIO's P/E ratio is -22.17. In terms of profitability, UTMD's ROE is +0.09%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, UTMD is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check HBIO's competition here
Milestone Scientific Inc. (AMEX: MLSS)
UTMD vs MLSS Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, MLSS has a market cap of 35.5M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while MLSS trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas MLSS's P/E ratio is -8.02. In terms of profitability, UTMD's ROE is +0.09%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, UTMD is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check MLSS's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
UTMD vs SDC Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas SDC's P/E ratio is -0.03. In terms of profitability, UTMD's ROE is +0.09%, compared to SDC's ROE of -1.96%. Regarding short-term risk, UTMD is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
UTMD vs IVC Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas IVC's P/E ratio is -0.79. In terms of profitability, UTMD's ROE is +0.09%, compared to IVC's ROE of -0.46%. Regarding short-term risk, UTMD is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
UTMD vs RVP Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while RVP trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas RVP's P/E ratio is -5.67. In terms of profitability, UTMD's ROE is +0.09%, compared to RVP's ROE of -0.05%. Regarding short-term risk, UTMD is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
UTMD vs BNGO Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, BNGO has a market cap of 17.9M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while BNGO trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas BNGO's P/E ratio is -0.36. In terms of profitability, UTMD's ROE is +0.09%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, UTMD is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check BNGO's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
UTMD vs ZJYL Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, ZJYL has a market cap of 15.6M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while ZJYL trades at $1.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas ZJYL's P/E ratio is 13.61. In terms of profitability, UTMD's ROE is +0.09%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, UTMD is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check ZJYL's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
UTMD vs RGNT Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, RGNT has a market cap of 12.6M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while RGNT trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas RGNT's P/E ratio is -0.07. In terms of profitability, UTMD's ROE is +0.09%, compared to RGNT's ROE of N/A. Regarding short-term risk, UTMD is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check RGNT's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
UTMD vs CUPR Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, CUPR has a market cap of 7.9M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while CUPR trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas CUPR's P/E ratio is -2.12. In terms of profitability, UTMD's ROE is +0.09%, compared to CUPR's ROE of -15.69%. Regarding short-term risk, UTMD is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check CUPR's competition here
Femasys Inc. (NASDAQ: FEMY)
UTMD vs FEMY Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, FEMY has a market cap of 7.7M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while FEMY trades at $2.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas FEMY's P/E ratio is -0.57. In terms of profitability, UTMD's ROE is +0.09%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, UTMD is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check FEMY's competition here
Lucyd, Inc (NASDAQ: LUCY)
UTMD vs LUCY Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, LUCY has a market cap of 5.2M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while LUCY trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas LUCY's P/E ratio is -0.49. In terms of profitability, UTMD's ROE is +0.09%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, UTMD is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
UTMD vs NSTG Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas NSTG's P/E ratio is -0.03. In terms of profitability, UTMD's ROE is +0.09%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, UTMD is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check NSTG's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
UTMD vs POAI Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas POAI's P/E ratio is -0.03. In terms of profitability, UTMD's ROE is +0.09%, compared to POAI's ROE of -21.19%. Regarding short-term risk, UTMD is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
UTMD vs MHUA Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas MHUA's P/E ratio is 0.25. In terms of profitability, UTMD's ROE is +0.09%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, UTMD is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
UTMD vs NXGL Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, NXGL has a market cap of 2.4M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while NXGL trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas NXGL's P/E ratio is -0.40. In terms of profitability, UTMD's ROE is +0.09%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, UTMD is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check NXGL's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
UTMD vs GMVD Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas GMVD's P/E ratio is -0.01. In terms of profitability, UTMD's ROE is +0.09%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, UTMD is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
UTMD vs GMVDW Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas GMVDW's P/E ratio is N/A. In terms of profitability, UTMD's ROE is +0.09%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, UTMD is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
UTMD vs AVGR Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas AVGR's P/E ratio is -0.05. In terms of profitability, UTMD's ROE is +0.09%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, UTMD is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
UTMD vs NXGLW Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, NXGLW has a market cap of 1.2M. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas NXGLW's P/E ratio is -0.02. In terms of profitability, UTMD's ROE is +0.09%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, UTMD is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
UTMD vs LUCYW Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas LUCYW's P/E ratio is N/A. In terms of profitability, UTMD's ROE is +0.09%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, UTMD is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check LUCYW's competition here
Analogic Corporation (NASDAQ: ALOG)
UTMD vs ALOG Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas ALOG's P/E ratio is 40.93. In terms of profitability, UTMD's ROE is +0.09%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, UTMD is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check ALOG's competition here
Invuity, Inc. (NASDAQ: IVTY)
UTMD vs IVTY Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas IVTY's P/E ratio is -3.80. In terms of profitability, UTMD's ROE is +0.09%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, UTMD is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check IVTY's competition here
IntriCon Corporation (NASDAQ: IIN)
UTMD vs IIN Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, IIN has a market cap of 0. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas IIN's P/E ratio is 226.45. In terms of profitability, UTMD's ROE is +0.09%, compared to IIN's ROE of -0.00%. Regarding short-term risk, UTMD is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check IIN's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
UTMD vs ATRS Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas ATRS's P/E ratio is 14.95. In terms of profitability, UTMD's ROE is +0.09%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, UTMD is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check ATRS's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
UTMD vs HRC Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, HRC has a market cap of 0. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas HRC's P/E ratio is 41.92. In terms of profitability, UTMD's ROE is +0.09%, compared to HRC's ROE of +0.14%. Regarding short-term risk, UTMD is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check HRC's competition here
Apria, Inc. (NASDAQ: APR)
UTMD vs APR Comparison September 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 237.6M. In comparison, APR has a market cap of 0. Regarding current trading prices, UTMD is priced at $74.40 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 22.08, whereas APR's P/E ratio is 22.59. In terms of profitability, UTMD's ROE is +0.09%, compared to APR's ROE of +9.81%. Regarding short-term risk, UTMD is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check APR's competition here